Conference Coverage

Sickle cell disease exacts a heavy vocational toll

Publish date: June 20, 2018

 

REPORTING FROM FSCDR 2018

Pages

Recommended Reading

FDA approves epoetin alfa biosimilar to treat anemia
MDedge Hematology and Oncology
Hematocrit improvement with SGLT2 inhibitor: Not just a diuretic effect?
MDedge Hematology and Oncology
FDA grants priority review to first-line SAA treatment
MDedge Hematology and Oncology
FDA approves long-acting ESA for dialysis-related anemia in children, adolescents
MDedge Hematology and Oncology
Family engagement can buffer early cognitive hit from SCD
MDedge Hematology and Oncology
Mircera approved for anemia in pediatric patients with CKD
MDedge Hematology and Oncology
FDA approves first biosimilar pegfilgrastim
MDedge Hematology and Oncology
Eltrombopag receives priority review designation for SAA
MDedge Hematology and Oncology
FDA places CTX001 for SCD on clinical hold
MDedge Hematology and Oncology
FDA approves first epoetin alfa biosimilar
MDedge Hematology and Oncology